Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

Tom Nolan reviews this week’s research Exercise for 30 minutes three times a week on an exercise bike for a month; then make the sessions an hour long and add resistance training with two sets of ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

SMALL heart size is linked to higher mortality risk in individuals with normal ejection fraction , particularly in women and those with high-normal ejection fraction.

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Cytokinetics (CYTK) announced that AMBER-HFpEF is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, ...